Payment overview · 2025
General Payments
$154.88
8 reported records · 5 companies
Healthcare provider profile · identity verified
Javier Andres Saenz, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LA JOYA, TX · NPI 1770781452
Verified facts
What the public records show
CMS Open Payments records show Javier Andres Saenz, M.D. received $154.88 in general payments during 2025 across 8 reported records.
Lilly USA, LLC accounted for 54.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 281 claims for Linzess by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 650 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 650 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 219 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $85.03 | 54.9% | 4 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $22.76 | 14.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.44 | 12.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.89 | 9.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.76 | 8.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $154.88 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $60.97 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.82 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 650 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 147 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
281 | 68 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
650 | 130 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
650 | 130 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
147 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
108 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
219 | 57 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
72 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2227 | 592 |
| Metformin Hcl | Metformin Hcl | 1300 | 321 |
| Losartan Potassium | Losartan Potassium | 1156 | 300 |
| Lisinopril | Lisinopril | 1108 | 294 |
| Gabapentin | Gabapentin | 1001 | 219 |
| Levothyroxine Sodium | Levothyroxine Sodium | 905 | 205 |
| Omeprazole | Omeprazole | 848 | 198 |
| Alendronate Sodium | Alendronate Sodium | 755 | 200 |
| Amlodipine Besylate | Amlodipine Besylate | 693 | 184 |
| Jardiance | Empagliflozin | 650 | 130 |
| Trazodone Hcl | Trazodone Hcl | 559 | 118 |
| Famotidine | Famotidine | 558 | 140 |
| Metoprolol Succinate | Metoprolol Succinate | 546 | 144 |
| Tamsulosin Hcl | Tamsulosin Hcl | 542 | 138 |
| Fluticasone Propionate | Fluticasone Propionate | 536 | 136 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 507 | 141 |
| Baclofen | Baclofen | 444 | 153 |
| Diclofenac Sodium | Diclofenac Sodium | 440 | 113 |
| Furosemide | Furosemide | 419 | 106 |
| Januvia | Sitagliptin Phosphate | 386 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 382 | 76 |
| Montelukast Sodium | Montelukast Sodium | 366 | 99 |
| Metoprolol Tartrate | Metoprolol Tartrate | 345 | 87 |
| Hydrochlorothiazide | Hydrochlorothiazide | 336 | 94 |
| Simvastatin | Simvastatin | 333 | 73 |
| Sertraline Hcl | Sertraline Hcl | 327 | 82 |
| Buspirone Hcl | Buspirone Hcl | 326 | 73 |
| Azithromycin | Azithromycin | 323 | 265 |
| Naproxen | Naproxen | 293 | 119 |
| Pantoprazole Sodium | Pantoprazole Sodium | 284 | 76 |
| Donepezil Hcl | Donepezil Hcl | 283 | 71 |
| Linzess | Linaclotide | 281 | 68 |
| Clopidogrel | Clopidogrel Bisulfate | 269 | 71 |
| Tradjenta | Linagliptin | 265 | 42 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 260 | 205 |
| Memantine Hcl | Memantine Hcl | 243 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 229 | 35 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 226 | 43 |
| Alcohol Pads | Alcohol Antiseptic Pads | 225 | 79 |
| Ezetimibe | Ezetimibe | 225 | 50 |
| Meclizine Hcl | Meclizine Hcl | 224 | 64 |
| Escitalopram Oxalate | Escitalopram Oxalate | 220 | 59 |
| Ozempic | Semaglutide | 219 | 57 |
| Meloxicam | Meloxicam | 197 | 55 |
| Single Use Swab | Alcohol Antiseptic Pads | 195 | 70 |
| Duloxetine Hcl | Duloxetine Hcl | 184 | 39 |
| Ibuprofen | Ibuprofen | 176 | 81 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 173 | 47 |
| Cilostazol | Cilostazol | 160 | 34 |
| Myrbetriq | Mirabegron | 158 | 26 |
| Mounjaro | Tirzepatide | 147 | 26 |
| Pro Comfort Pen Needle | Pen Needle, Diabetic | 142 | 33 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 136 | 122 |
| Mupirocin | Mupirocin | 128 | 85 |
| Fenofibrate | Fenofibrate Nanocrystallized | 121 | 29 |
| Farxiga | Dapagliflozin Propanediol | 120 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 116 | 31 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 114 | 35 |
| Glipizide | Glipizide | 112 | 28 |
| Nystatin | Nystatin | 112 | 48 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 108 | 28 |
| Nifedipine Er | Nifedipine | 108 | 35 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 108 | 23 |
| Trulicity | Dulaglutide | 108 | 36 |
| Allopurinol | Allopurinol | 105 | 27 |
| Cefdinir | Cefdinir | 104 | 94 |
| Finasteride | Finasteride | 104 | 26 |
| Dicyclomine Hcl | Dicyclomine Hcl | 98 | 32 |
| Carvedilol | Carvedilol | 96 | 27 |
| Fluconazole | Fluconazole | 93 | 65 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 26 |
| Tresiba Flextouch U-100 | Insulin Degludec | 87 | 23 |
| Xarelto | Rivaroxaban | 83 | 15 |
| Potassium Chloride | Potassium Chloride | 80 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 77 | 21 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 73 | 30 |
| Constulose | Lactulose | 73 | 19 |
| Clonidine Hcl | Clonidine Hcl | 72 | 19 |
| Rybelsus | Semaglutide | 72 | 17 |
| Atenolol | Atenolol | 69 | 19 |
| Solifenacin Succinate | Solifenacin Succinate | 68 | 13 |
| Procto-Med Hc | Hydrocortisone | 65 | 18 |
| Sulfasalazine | Sulfasalazine | 65 | 15 |
| Eliquis | Apixaban | 62 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 62 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 62 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 40 |
| Enalapril Maleate | Enalapril Maleate | 59 | 18 |
| Dutasteride | Dutasteride | 56 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 49 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 53 | 15 |
| Clotrimazole | Clotrimazole | 52 | 20 |
| Vascepa | Icosapent Ethyl | 52 | 16 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 51 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 48 | 29 |
| Ondansetron Odt | Ondansetron | 47 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 15 |
| Lorazepam | Lorazepam | 46 | 15 |
| Olanzapine | Olanzapine | 46 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 25 |
| True Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 46 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 13 |
| Levemir Flexpen | Insulin Detemir | 40 | 14 |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | 14 |
| Amoxicillin | Amoxicillin | 38 | 36 |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 38 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 38 | 12 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 14 |
| Cephalexin | Cephalexin | 36 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 12 |
| Prednisone | Prednisone | 36 | 33 |
| Alprazolam | Alprazolam | 35 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 35 | 12 |
| Lovastatin | Lovastatin | 35 | suppressed |
| Valsartan | Valsartan | 35 | suppressed |
| Sucralfate | Sucralfate | 34 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 12 |
| Ketoconazole | Ketoconazole | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Telmisartan | Telmisartan | 32 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 32 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 30 | 12 |
| Levofloxacin | Levofloxacin | 29 | 26 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Repaglinide | Repaglinide | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Glimepiride | Glimepiride | 23 | suppressed |
| Terconazole | Terconazole | 23 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 23 | 11 |
| Hydrocortisone | Hydrocortisone | 22 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 14 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 20 |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 18 |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 13 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 19 | 17 |
| Pentoxifylline | Pentoxifylline | 19 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 18 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 18 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Erythromycin | Erythromycin Base | 17 | 16 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 14 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Insulin Degludec Pen (U-200) | Insulin Degludec | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | 11 |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Travoprost | Travoprost | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Glipizide Er | Glipizide | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Neupro | Rotigotine | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $154.88 · 8 records | Lilly USA, LLC | FUROSCIX, JARDIANCE, MOUNJARO, VRAYLAR, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error